The Claim
Among 35,826 patients hospitalized for myocardial infarction, 16.9% received early ezetimibe treatment within 12 weeks, 18.1% received late ezetimibe between 13 weeks and 16 months, and 65.0% did not receive ezetimibe at all, despite all groups having at least 98% high-intensity statin use.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Out of nearly 36,000 people hospitalized for heart attacks, most didn't get a cholesterol drug called ezetimibe—even though almost all were already on strong statins. Only about 1 in 6 got it early, and a similar number got it later.
See the scientific wording
Among 35,826 patients hospitalized for myocardial infarction, only 16.9% received early ezetimibe (within 12 weeks), 18.1% received it late (13 weeks to 16 months), and 65.0% did not receive ezetimibe at all, despite all groups having ≥98% high-intensity statin use.
What the research says
1 studyThe study looked at when heart attack patients started taking ezetimibe and found that most didn’t get it early—or at all—just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.